Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
HAEMATO AG, headquartered in Germany, is a prominent player in the pharmaceutical industry, specialising in the development and distribution of innovative therapies for patients with rare diseases and complex health conditions. Founded in 1993, the company has established a strong presence across Europe, focusing on key operational regions such as Germany and other EU countries.
With a commitment to enhancing patient care, HAEMATO AG offers a diverse portfolio of products, including specialty pharmaceuticals and biosimilars, which are distinguished by their high quality and efficacy. The company has achieved significant milestones, positioning itself as a trusted partner in the healthcare sector, known for its dedication to research and development. HAEMATO AG continues to make strides in the market, contributing to advancements in treatment options and improving the lives of patients worldwide.
-19 vs industry average
HAEMATO AG’s score of 23 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for HAEMATO AG yet.
HAEMATO AG, headquartered in Germany, currently does not report any specific carbon emissions data for the most recent year. As a result, there are no available figures for total emissions, including Scope 1, Scope 2, or Scope 3 emissions.
The company has not outlined any reduction targets or climate commitments in the provided data. Additionally, there are no initiatives reported under the Science Based Targets initiative (SBTi) or other climate pledges.
It is important to note that HAEMATO AG is a current subsidiary, and any potential emissions data or climate commitments may be cascaded from its parent organization. However, specific details regarding such cascaded data are not available at this time.
In the absence of concrete emissions data, HAEMATO AG's climate strategy and commitments remain unclear, reflecting a broader context within the industry where transparency and accountability in carbon emissions reporting are increasingly critical.
No climate goals have been disclosed for HAEMATO AG yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more